Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03860558 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Impact of Metabolic Health on Sperm Epigenetic Marks in Humans

StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 6, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jul 1, 2025 to Jul 1, 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v7
  2. Primary and study completion dates: Jul 1, 2024 to Jul 1, 2025v6
  3. Primary and study completion dates: Jul 1, 2023 to Jul 1, 2024v5
  4. Primary and study completion dates: May 2022 to Jul 1, 2023
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 2 of 2 entries
    v4
  5. Study description expanded, about 32 wordsv3
  6. Primary and study completion dates: May 2019 to May 2022v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Joslin Diabetes Center
22 trials monitored
See all monitored trials
Diabetes
5,087 trials monitored
See 222 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
and 1 more disease
This study is designed to evaluate whether epigenetic markers in overweight men with type 1 diabetes (T1D) or type 2 diabetes (T2D) can be improved with a 3 month lifestyle intervention or program focused in glycemic intervention.
Trial Details
NCT Number NCT03860558
Lead Sponsor Joslin Diabetes Center
Conditions
(from sponsor)		 Overweight, Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Related terms Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Overweight
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov